American Association for Cancer Research
ccr-23-0215_figure_s7_suppfs7.pdf (93.34 kB)

Figure S7 from Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma

Download (93.34 kB)
journal contribution
posted on 2023-08-01, 08:40 authored by Brooke Horowitch, Daniel Y. Lee, Min Ding, Sandra Martinez-Morilla, Thazin Nwe Aung, Feriel Ouerghi, Xueting Wang, Wei Wei, William Damsky, Mario Sznol, Harriet Kluger, David L. Rimm, Jeffrey J. Ishizuka

Supplemental Figure 7: pSTAT1Y701, CD3, and driver mutation status in tumors based on combined STAT1 and PD-L1 status.


National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

Melanoma Research Alliance (MRA)

Yale SPORE in Skin Cancer

National Cancer Institute

Find out more...



IFN signaling in the tumor microenvironment is a critical determinant of both response and resistance of cancer to immune checkpoint inhibitors (ICI). We hypothesized that distinct patterns of IFN signaling in melanoma are associated with clinical response or resistance to ICIs. Two tissue microarrays containing samples from 97 patients with metastatic melanoma who received nivolumab, pembrolizumab, or a combination of ipilimumab and nivolumab at Yale New Haven Hospital between 2011 and 2017 were randomized into discovery and validation cohorts. Samples were stained and visualized using multiplexed immunofluorescence microscopy for STAT1, STAT1 phosphorylated at Y701 (pSTAT1Y701), and PD-L1, and signals were quantified using the automated quantitative analysis method of quantitative immunofluorescence. Treatment response was assessed using RECIST, and overall survival was analyzed. For in vitro studies, human melanoma cell lines were stimulated with IFNγ and IFNβ, and Western blotting was performed. Pretreatment STAT1 levels were higher in responders to ICIs [complete response/partial response/stable disease (SD) for > 6 months] than in nonresponders (SD < 6 months/progressive disease). Higher pretreatment STAT1 levels were associated with improved survival after ICIs in both the discovery and validation cohorts. Western blot analysis of human melanoma cell lines stimulated with IFN demonstrated distinct patterns of upregulation of STAT1 compared with pSTAT1Y701 and PD-L1. When combining STAT1 and PD-L1 markers, patients with STAT1highPD-L1low tumors had improved survival compared with those with STAT1lowPD-L1high tumors. STAT1 may better predict melanoma response to ICIs than current strategies, and combined STAT1 and PD-L1 biomarkers may provide insight into IFN-responsive versus IFN-resistant states.

Usage metrics

    Clinical Cancer Research





    Ref. manager